These results further demonstrated that LWBQ capsules could inhibit the expression of STAT4/STAT6 and MMP-9/TIMP-1 and control the pulmonary inflammatory response in COPD patients. This evidence concerns the gene STAT6 and chronic obstructive pulmonary disease.